Tetracycline-inducible RNAi Knockdown of SCL (Stem Cell Leukaemia) in Mice

RNAi (RNA interference) is a powerful technology for sequence-specific targeting of mRNAs. This thesis was aimed at establishing conditions for conditional RNAi-mediated silencing first in vitro and subsequently also in transgenic mice. As a target the basic helix-loop-helix transcription factor encoding gene SCL (stem cell leukaemia also known as Tal-1 or TCL5) was used. SCL is a key regulator for haematopoietic development and ectopic expression of SCL is correlated with acute T-lymphoblastic leukaemias. Loss of SCL function studies demonstrated that ab initio deletion of SCL resulted in embryonic lethality around day E9 in gestation. To be able to conditionally inactivate SCL, RNAi technology was combined with the tetracycline-dependent regulatory system. This strategy allowed to exogenously control the induction of RNAi in a reversible fashion and consequently the generation of a completely switchable RNAi knockdown. First a suitable vector allowing for co-expression of tetracycline-controlled shRNAs (small hairpin RNAs) and constitutively active EGFP (enhanced green fluorescent protein) was generated. This novel vector, pRNAi-EGFP, was then evaluated for EGFP expression and tetracycline-mediated expression of shRNAs. Four sequences targeting different regions within the SCL mRNA were tested for their efficiency to specifically knockdown SCL. These experiments were performed in M1 murine leukaemia cells and subsequently in the HEK 293 cell line, expressing an engineered HA-tagged SCL protein. The second assay provided a solid experimental method for determining the efficiency of different SCL-siRNA knockdown constructs in tissue culture. Western blotting analyses revealed a down regulation of SCL protein for all four tested SCL-specific target sequences albeit with different knockdown efficiencies (between 25% and 100%). Furthermore, stringent tetracycline-dependent switchability of shRNA expression was confirmed by co-transfecting the SCL-specific pRNAi-EGFP vector (SCL-siRNA) together with the HA-tagged SCL expression plasmid into the HEK 293TR /T-REx cell line constitutively expressing the tetracycline repressor (TetR). These series of experiments demonstrated tight regulation of siRNA expression without background activity. To be able to control the SCL knockdown in vivo and especially to circumvent any possible embryonic lethality a transgenic mouse line with general expression of a tetracycline repressor was needed. Two alternative methods were used to generate TetR mice. The first approach was to co-inject the tetracycline-regulated RNAi vector together with a commercially available and here specifically modified T-REx expression vector (SCL-siRNA T-REx FRT LoxP mouse line). The second method involved the generation of a TetR expressor mouse line, which was then used for donating TetR-positive oocytes for pronuclear injection of the RNAi vector (SCL-siRNA T-REx mouse line). As expected, and in agreement with data from conditional Cre-controlled adult SCL knockout mice, post-transcriptional silencing of SCL by RNAi caused a shift in the maturation of red blood cell populations. This was shown in the bone marrow and peripheral blood by FACS analysis with the red blood cell-specific TER119 and CD71 markers which can be used to define erythrocyte differentiation (Lodish plot technique). In conclusion this study established conditions for effective SCL RNAi-mediated silencing in vitro and in vivo providing an important tool for further investigations into the role of SCL and, more generally, of its in vivo function in haematopoiesis and leukaemia. Most importantly, the here acquired knowledge will now allow the establishment of other completely conditional and reversible knockdown phenotypes in mice.

Konditionale Mutagenese von Desmoglein 2 in der Maus

Desmosomen sind hoch organisierte interzelluläre Verbindungen, die Zellverbänden eine mechanische Stabilität verleihen. Die Intermediärfilamentnetzwerke benachbarter Zellen werden mit Hilfe der desmosomalen Cadherine vom Desmoglein- und Desmocollin-Typ miteinander verknüpft. Diese Glykoproteine interagieren miteinander im Interzellularspalt zwischen benachbarten Zellen und stellen mit ihren zytoplasmatischen Domänen einen Ankerpunkt für desmosomale Brückenproteine dar, an welche wiederum die Proteine des Intermediärfilament-Zytoskeletts binden. Bei der Maus spielt das desmosomale Cadherin Desmoglein 2 (DSG2) bereits in frühen Stadien der Embryogenese eine entscheidende Rolle. Homozygote DSG2-Knockout-Mäuse sterben bereits vor der Implantation des Embryos ab. Im adulten Tier ist Dsg2 die am weitesten verbreitete Isoform, in Darm, Leber und Herzmuskel wird es zudem exklusiv exprimiert. Ziel dieser Arbeit war es, die Bedeutung von Dsg2 in differenzierten Gewebeverbänden adulter Tiere zu untersuchen. Im Rahmen dieser Doktorarbeit wurden mehrere transgene Mauslinien hergestellt, in denen mit Hilfe des Cre/loxP-Systems eine Deletion im DSG2-Gen konditional und gewebsspezifisch induziert werden konnte. Dazu wurden zuerst zwei loxP-Sequenzen und eine mit zwei FRT-Stellen flankierte Neomyzinresistenzgen-Kassette in das DSG2-Gen von embryonalen Stammzellen durch homologe Rekombination eines Targeting-Konstrukts inseriert. Diese Zellen wurden in Blastozysten injiziert und Mauslinien hergestellt. Mit Hilfe der Flpe-Rekombinase wurde anschließend die Resistenzenzgen-Kassette entfernt. Diese Stämme wurden mit Mäusen verpaart, die eine induzierbare und gewebsspezifische Synthese der Cre-Rekombinase ermöglichen. Im Darmepithel und der Leber konnte eine gewebsspezifische Rekombination des DSG2-Gens induziert werden. Untersuchungen der DSG2-mRNA zeigten, dass die DSG2-Rekombination in der Darmschleimhaut nahezu vollständig erfolgte. Immunfluoreszenz-Analysen an Gewebsfragmenten induzierter Tiere mit Isotyp-spezifischen Antikörpern, die im Rahmen dieser Arbeit hergestellt worden waren, zeigten jedoch keine signifikanten Unterschiede der Desmosomenzahl und -verteilung. Daher wurden eGFP-Hybride des zu erwartenden mutierten Dsg2-Proteins in Zellen exprimiert und mit wildtypischem Dsg2 verglichen. Es konnte hinsichtlich der Verteilung und Morphologie der Desmosomen keine Unterschiede zwischen beiden Dsg2-Proteinen festgestellt werden. Der Dsg2-Mutante fehlen wichtige Proteinbereiche, die für die trans-Interaktion der extrazellulären Domäne verantwortlich sind, die Haupt-N-Glykosylierungsstelle, sowie eine der insgesamt vier Kalzium-Bindestellen. Dies sind Eigenschaften, von denen man bisher annahm, dass sie eine zentrale Bedeutung für die desmosomale Adhäsion besitzen. Weitere Experimente werden zeigen, inwieweit die hergestellte Dsg2-Mutante in „Stresssituationen“, wie sie z.B. bei Regenerationsvorgängen oder der Tumorgenese auftreten, zu veränderten adhäsiven Eigenschaften führt.

Gene therapy for a novel mouse model of Canavan disease

Canavan disease (CD) is a rare leukodystrophy caused by loss-of-function mutations in the gene encoding aspartoacylase (ASPA), an oligodendrocyte-enriched enzyme. It is characterised by the accumulation of the ASPA substrate N-acetylaspartate (NAA) in brain, blood and urine, leading to a spongiform vacuolisation of the brain, severe motoric and cognitive impairments and premature death. To date, no therapy is available due to the lack of a gene-transfer system allowing transgene expression in oligodendrocytes (OLs) and the restoration of the missing enzyme. Hence, the aim of this study was to establish a novel gene-transfer system and its preclinical evaluation in a CD animal model.rnIn the first part of this thesis, a novel ASPA mouse mutant was generated. A βgeo cassette (including the genes encoding β-galactosidase and neomycin) flanked by frt sites was inserted into intron 1 of the intact aspa gene. Additionally, exon 2 was flanked by loxP sites for optional conditional deletion of the targeted locus. The resulting ASPA-deficient aspalacZ/lacZ-mouse was found to be an accurate model of CD and an important tool to identify novel aspects of its complex pathology. Homozygous mutants showed a CD-like histopathology, neurological impairment, behavioural deficits as well as a reduced body weight. Additionally, MRI data revealed changes in brain metabolite composition. rnRecombinant adeno-associated viral (rAAV) vectors have become a versatile tool for gene transfer to the central nervous system because they are efficient, non-toxic and replication-deficient. Based on the natural neurotropism of AAV vectors, AAV-based gene delivery has entered the clinics for the treatment of neurodegenerative diseases. However, the lack of AAV vectors with oligodendroglial tropism has precluded gene therapy for leukodystrophies. In the second part of this work, it was shown that the transduction profile of established AAV serotypes can be targeted towards OLs in a transcriptional approach, using the oligodendrocyte-specific myelin basic protein (MBP) promoter to drive transgene expression in OLs.rnIn the last part of this work, the therapeutic efficacy of AAV-mediated aspa gene transfer to OLs of juvenile aspalacZ/lacZ mice was evaluated. AAV-aspa injections into multiple sites of the brain parenchyma resulted in transduction of OLs in the grey and white matter throughout the brain. Histological abnormalities in the brain of ASPA-deficient mice were ameliorated and accompanied by a reduction of NAA levels. Furthermore, the treatment resulted in normalisation of body weight, motor function and nest-building behaviour. These data provide a proof-of-concept for a successful gene therapy of Canavan disease. This might pave the way towards translation into clinical application and serve as the basis for the genetic treatment of other leukodystrophies.